1. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). (March 2022) Authors: Li, Meichen; Hou, Xue; Chen, Jing; Zhang, Baishen; Wang, Na; Han, Hongyu; Chen, Likun Journal: Lung cancer Issue: Volume 165(2022) Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. (April 2023) Authors: Wang, Na; Zheng, Lie; Li, Meichen; Hou, Xue; Zhang, Baishen; Chen, Jing; Li, Su; Chen, Likun Journal: Lung cancer Issue: Volume 178(2023) Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparing organ‐specific immune‐related adverse events for immune checkpoint inhibitors: A Bayesian network meta‐analysis. Issue 2 (21st January 2021) Authors: Li, Meichen; Hou, Xue; Chen, Jing; Yu, Juan; Chen, Meiting; Wang, Na; Zhang, Baishen; Chen, Likun Journal: Clinical and translational medicine Issue: Volume 11:Issue 2(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060). (31st December 2022) Authors: Li, Meichen; Hou, Xue; Sai, Ke; Wu, Lihong; Chen, Jing; Zhang, Baishen; Wang, Na; Wu, Lijia; Zheng, Hongbo; Zhang, Jiao; Mou, Yonggao; Chen, Likun Journal: Oncoimmunology Issue: Volume 11:Number 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗